In the most recent trading session, Gilead Sciences (GILD) closed at $93.85, indicating a -1.57% shift from the previous trading day.

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $115.00.

Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Tyler Van Buren, an analyst from TD Cowen, maintained the Buy rating on Gilead Sciences (GILD – Research Report). The associated price target ...

In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of ...

Lynda Carter and Jessica Carter Altman had a fun mother-daughter date during Paris Fashion Week. The "Wonder Woman" star ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...

Plc (LSE: GILD), a company recognized for its engagement in competitive gaming, has officially rebranded to Cassell Capital Plc, as confirmed by the issuance of a new Certificate of Incorporation.

The stock's fall snapped a two-day winning streak.